Characterization of phosphodiesterase 2A in human malignant melanoma PMP cells

Morita,Hiroshi; Murata,Taku; Shimizu,Kasumi; Okumura,Kenya; Inui,Madoka; Tagawa,Toshiro

doi:10.3892/or.2013.2260

Characterization of phosphodiesterase 2A in human malignant melanoma PMP cells

Authors:
- Hiroshi Morita
- Taku Murata
- Kasumi Shimizu
- Kenya Okumura
- Madoka Inui
- Toshiro Tagawa
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, Department of Clinical Sciences, Medical Life Science, Mie University Graduate School of Medicine, Tsu, Mie, Japan
Published online on: January 31, 2013 https://doi.org/10.3892/or.2013.2260
Pages: 1275-1284
Copyright: © Morita et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The prognosis for malignant melanoma is poor; therefore, new diagnostic methods and treatment strategies are urgently needed. Phosphodiesterase 2 (PDE2) is one of 21 phosphodiesterases, which are divided into 11 families (PDE1-PDE11). PDE2 hydrolyzes cyclic AMP (cAMP) and cyclic GMP (cGMP), and its binding to cGMP enhances the hydrolysis of cAMP. We previously reported the expression of PDE1, PDE3 and PDE5 in human malignant melanoma cells. However, the expression of PDE2 in these cells has not been investigated. Herein, we examined the expression of PDE2A and its role in human oral malignant melanoma PMP cells. Sequencing of RT-PCR products revealed that PDE2A2 was the only variant expressed in PMP cells. Four point mutations were detected; one missense mutation at nucleotide position 734 (from C to T) resulted in the substitution of threonine with isoleucine at amino acid position 214. The other three were silent mutations. An in vitro migration assay and a terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling assay revealed that suppressing PDE2 activity with its specific inhibitor, erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA), had no impact on cell motility or apoptosis. Furthermore, the cytotoxicity of EHNA, assessed using a trypan blue exclusion assay, was negligible. On the other hand, assessment of cell proliferation by BrdU incorporation and cell cycle analysis by flow cytometry revealed that EHNA treatment inhibited DNA synthesis and increased the percentage of G2/M-arrested cells. Furthermore, cyclin A mRNA expression was downregulated, while cyclin E mRNA expression was upregulated in EHNA-treated cells. Our results demonstrated that the PDE2A2 variant carrying point mutations is expressed in PMP cells and may affect cell cycle progression by modulating cyclin A expression. Thus, PDE2A2 is a possible new molecular target for the treatment of malignant melanoma.

View Figures

View References

1	Thompson JF, Scolyer RA and Kefford RF: Cutaneous melanoma. Lancet. 365:687–701. 2005. View Article : Google Scholar : PubMed/NCBI
2	Beavo JA, Houslay MD and Francis SH: Cyclic nucleotide phosphodiesterase superfamily. Cyclic Nucleotide Phosphodiesterases in Health and Disease. Beavo JA, Francis SH and Houslay MD: CRC Press; Boca Raton: pp. 3–17. 2007
3	Houslay MD: Underpinning compartmentalised cAMP signalling through targeted cAMP breakdown. Trends Biochem Sci. 35:91–100. 2009. View Article : Google Scholar : PubMed/NCBI
4	Martinez SE: PDE2 structure and functions. Cyclic Nucleotide Phosphodiesterases in Health and Disease. Beavo JA, Francis SH and Houslay MD: CRC Press; Boca Raton: pp. 55–77. 2007
5	Conti M and Beavo J: Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem. 76:481–511. 2007. View Article : Google Scholar : PubMed/NCBI
6	Lugnier C: Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther. 109:366–398. 2006. View Article : Google Scholar : PubMed/NCBI
7	Shimizu K, Murata T, Watanabe Y, Sato C, Morita H and Tagawa T: Characterization of phosphodiesterase 1 in human malignant melanoma cell lines. Anticancer Res. 29:1119–1122. 2009.PubMed/NCBI
8	Murata T, Shimizu K, Narita M, Manganiello VC and Tagawa T: Characterization of phosphodiesterase 3 in human malignant melanoma cell line. Anticancer Res. 22:3171–3174. 2002.PubMed/NCBI
9	Murata T, Shimizu K, Watanabe Y, Morita H, Sekida M and Tagawa T: Expression and role of phosphodiesterase 5 in human malignant melanoma cell line. Anticancer Res. 30:355–358. 2010.PubMed/NCBI
10	Kamei T, Inui M, Nakamura S, Okumura K, Goto A and Tagawa T: Interferon-γ and anti-Fas antibody-induced apoptosis in human melanoma cell lines and its relationship to bcl-2 cleavage and bak expression. Melanoma Res. 13:153–159. 2003.
11	Omori K and Kotera J: Overview of PDEs and their regulation. Circ Res. 100:309–327. 2007. View Article : Google Scholar : PubMed/NCBI
12	Kambayashi J, Shakur Y and Liu Y: Bench to bedside: multiple actions of the PDE3 inhibitor cilostazol. Cyclic Nucleotide Phosphodiesterases in Health and Disease. Beavo JA, Francis SH and Houslay MD: CRC Press; Boca Raton: pp. 627–648. 2007
13	Kim DH and Lerner A: Type 4 cyclic adenosine monophosphate phosphodiesterase as a therapeutic target in chronic lymphocytic leukemia. Blood. 92:2484–2494. 1998.PubMed/NCBI
14	Morris HR, Taylor GW, Masento MS, Jermyn KA and Kay RR: Chemical structure of the morphogen differentiation inducing factor from Dictyostelium discoideum. Nature. 328:811–814. 1987. View Article : Google Scholar : PubMed/NCBI
15	Shimizu K, Murata T, Tagawa T, Takahashi K, Ishizawa R, Abe Y, Hosaka K and Kubohara Y: Calmodulin-dependent cyclic nucleotide phosphodiesterase (PDE1) is a pharmacological target of differentiation-inducing factor-1, an antitumor agent isolated from Dictyostelium. Cancer Res. 64:2568–2571. 2004. View Article : Google Scholar
16	Favot L, Keravis T, Holl V, Le Bec A and Lugnier C: VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors. Thromb Haemost. 90:334–343. 2003.PubMed/NCBI
17	Drees M, Zimmermann R and Eisenbrand G: 3′,5′-Cyclic nucleotide phosphodiesterase in tumor cells as potential target for tumor growth inhibition. Cancer Res. 53:3058–3061. 1993.
18	Dunkern TR and Hatzelmann A: Characterization of inhibitors of phosphodiesterase 1C on a human cellular system. FEBS J. 274:4812–4824. 2007. View Article : Google Scholar : PubMed/NCBI
19	Rosman GJ, Martins TJ, Sonnenburg WK, Beavo JA, Ferguson K and Loughney K: Isolation and characterization of human cDNAs encoding a cGMP-stimulated 3′,5′-cyclic nucleotide phosphodiesterase. Gene. 191:89–95. 1997.PubMed/NCBI
20	Seybold J, Thomas D, Witzenrath M, Boral S, Hocke AC, Bürger A, Hatzelmann A, Tenor H, Schudt C, Krüll M, Schütte H, Hippenstiel S and Suttorp N: Tumor necrosis factor-α-dependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. Blood. 105:3569–3576. 2005.
21	Ahlström M, Pekkinen M, Huttunen M and Lamberg-Allardt C: Dexamathasone down-regulates cAMP-phosphodiesterase in human osteosarcoma cells. Biochem Pharmacol. 69:267–275. 2005.PubMed/NCBI
22	Gupta R, Kumar G and Kumar RS: An update on cyclic nucleotide phosphodiesterase (PDE) inhibitors: phosphodiesterases and drug selectivity. Methods Find Exp Clin Pharmacol. 27:101–118. 2005. View Article : Google Scholar : PubMed/NCBI
23	Acin-Perez R, Russwurm M, Günnewig K, Gertz M, Zoidl G, Ramos L, Buck J, Levin LR, Rassow J, Manfredi G and Steegborn C: A phosphodiesterase 2A isoform localized to mitochondria regulates respiration. J Biol Chem. 286:30423–30432. 2011. View Article : Google Scholar : PubMed/NCBI
24	Netherton SJ and Maurice DH: Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis. Mol Pharmacol. 67:263–272. 2005. View Article : Google Scholar : PubMed/NCBI
25	Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, Sperl G, Ahnen D and Pamukcu R: Exisulind induction of apoptosis involves guanosin 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated β-catenin. Cancer Res. 60:3338–3342. 2000.PubMed/NCBI
26	Favot L, Keravis T and Lugnier C: Modulation of VEGF-induced endothelial cell cycle protein expression through cyclic AMP hydrolysis by PDE2 and PDE4. Thromb Haemost. 92:634–645. 2004.PubMed/NCBI
27	Pawlik TM and Keyomarsi K: Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys. 59:928–942. 2004. View Article : Google Scholar : PubMed/NCBI
28	Khan AJ, Wall B, Ahlawat S, Green C, Schiff D, Mehnert JM, Goydos JS, Chen S and Haffty BG: Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo. Clin Cancer Res. 17:1807–1814. 2011. View Article : Google Scholar
29	Johnson GE, Ivanov VN and Hei TK: Radiosensitization of melanoma cells through combined inhibition of protein regulations of cell survival. Apoptosis. 13:790–802. 2008. View Article : Google Scholar : PubMed/NCBI